Phosphodiesterase type 5 inhibitors: state of the therapeutic class (Q36993658)

17 August 2017

1 reference

title

Phosphodiesterase type 5 inhibitors: state of the therapeutic class (English)

1 reference

17 August 2017

Culley C Carson

1

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Urologic Clinics of North America

17 August 2017

published in

1 reference

17 August 2017

volume

34

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

507-15, vi

1 reference

Phosphodiesterase type 5 inhibitors for erectile dysfunction

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Mechanisms of action of PDE5 inhibition in erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Cyclic nucleotide phosphodiesterases: relating structure and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

The efficacy and safety of tadalafil: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Oral drug therapy for erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Effects of sildenafil citrate (Viagra) combined with nitrate on the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Time course of the interaction between tadalafil and nitrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Effects of grapefruit juice on the pharmacokinetics of sildenafil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

No adverse hemodynamic interaction between sildenafil and red wine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Long-term use of sildenafil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Efficacy and safety of tadalafil in men with severe erectile dysfunction in tertiary care academic centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Effects of tadalafil on erectile dysfunction in men with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Safety and Efficacy of Vardenafil for the Treatment of Men With Erectile Dysfunction After Radical Retropubic Prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Sildenafil influences lower urinary tract symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Erectile dysfunction and treatment of carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Phosphodiesterases regulate airway smooth muscle function in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

Cardiovascular effects of phosphodiesterase 5 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.013

10.1016/J.UCL.2007.08.013

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference